南京医科大学学报（自然科学版）2025，Vol.45Issue(3)：404-417,14.DOI:10.7655/NYDXBNSN241237
帕金森病标志物α-突触核蛋白聚集抑制剂的研究进展
Research progress on inhibitors of α-synuclein aggregation,a marker for Parkinson's disease
摘要
Abstract
Parkinson's disease(PD)is the second most common neurodegenerative disease.The pathological aggregation of α-synuclein(α-syn)is a biomarker of PD,which is closely related to the occurrence and development of PD.Finding an inhibitor that can inhibit the formation of pathological aggregates such as α-syn oligomer and α-syn protofibrils at the early stage of the disease is of great significance for the treatment of PD.In recent years,significant progress has been made in the research of inhibitors targeting α-syn aggregation.This review summarizes the structure,physiological function,pathological mechanism and inhibitors of α-syn aggregation,aiming to provide a reference for the further research and development of α-syn aggregation inhibitors.关键词
帕金森病/α-突触核蛋白/聚集抑制剂Key words
Parkinson's disease/α-synuclein/aggregation inhibitor分类
医药卫生引用本文复制引用
李奇,秦亚娟,唐立钧..帕金森病标志物α-突触核蛋白聚集抑制剂的研究进展[J].南京医科大学学报（自然科学版）,2025,45(3):404-417,14.基金项目
国家自然科学基金(82373728,82473768) （82373728,82473768）
江苏省自然科学基金(BK20231266) （BK20231266）
